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Abstract 
  
Matrix metalloproteinase-9 (MMP-9)/gelatinase B is over-expressed in pancreatic ductal 
adenocarcinoma (PDAC) and plays a central role in tumour cell invasion and metastasis. We here 
complemented mechanistic insights in the cancer biology of MMP-9 and investigated the effects of 
specific long-term loss-of-function of MMP-9 on PDAC initiation and progression by genetic ablation 
in a well-established mouse model of spontaneous PDAC. Tumour growth and progression were 
analysed by histopathology and immunohistochemistry. Invasive growth of PDAC cells was analysed 
in vitro (proliferation, survival, migration, invasion assays) and in vivo (experimental metastasis assays). 
Retroviral shRNAi was used to knock-down target genes (MMP-9, IL-6R). Gene expression was 
analysed by qRT-PCR, Western Blot, ELISA, in situ hybridization and zymography. PDAC tumours 
from MMP-9-deficient mice were dramatically larger, more invasive and contained more stroma. Yet, 
ablation of MMP-9 in PDAC cells did not directly promote invasive growth. Interestingly, systemic 
ablation of MMP-9 led to increased IL-6 levels resulting from abrogation of MMP-9-dependent SCF-
signalling in the bone marrow (BM). IL-6 levels in MMP-9-/- mice were sufficient to induce invasive 
growth and STAT3 activation in PDAC cells via IL-6 receptor (IL-6R). Interference with IL-6R blocked 
the increased invasion and metastasis of PDAC cells in MMP-9-deficient hosts. In conclusion, ablation 
of systemic MMP-9 initiated fatal communication between maintenance of physiological functions of 
MMP-9 in the BM and invasive growth of PDAC via the IL-6/IL6R/STAT3 axis. Thus, the beneficial 
effects of host MMP-9 on PDAC are an important caveat for the use of systemic MMP-9 inhibitors in 
cancer. 
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Introduction 
 
Pancreatic cancer is a lethal malignancy, characterized by aggressive local invasion and metastatic 
spread (1). Pancreatic ductal adenocarcinoma (PDAC) is the predominant form of pancreatic cancer 
accounting for >90% of the diagnosed cases (1). Currently, treatment options for PDAC are scarce (1) 
and new therapeutic targets are subject to intensive research (2,3). Matrix metalloproteinases (MMPs) 
are zinc-dependent proteases that contribute to development and tissue homeostasis, and modulate 
cancer progression by digesting a variety of substrates (4). The functions of MMPs in extracellular 
matrix (ECM) degradation, invasive growth and angiogenesis led to the assumption that inhibition of 
catalytic MMP activity in vivo would have an anti-tumourigenic effect (5). However, clinical trials on 
MMP inhibitors failed to demonstrate clinical beneﬁt and in some cases even showed adverse effects on 
the patient´s outcome (5). One explanation for this unexpected failure was that broad-spectrum 
inhibition of MMPs gave rise to a metastasis-promoting environment in the liver (6). Later it was 
discovered that some MMPs even have protective, anti-tumourigenic functions (7) from which it was 
concluded that target MMPs have to be inhibited selectively to inhibit cancer growth and metastasis 
(7,8). Within the whole MMP family, MMP-9 is considered an especially compelling target, given a 
large body of evidence demonstrating a key role for MMP-9 in tumourigenesis and metastasis (9). 
Recently, inhibition of MMP-9 was again suggested as a potential therapeutic approach (10) and novel, 
selective MMP-9-inhibitory antibodies are currently tested in clinical trials (11). However, it is 
important to note that MMP-9 is also involved in physiological processes so that the functional role of 
MMP-9 needs to be carefully defined for the individual disease context (12), before a final conclusion 
about its precise function can be drawn. In addition, MMP-9 also has non-catalytic activities in tumour 
biology (13). 
Previous studies addressed the role of MMP-9 in pancreatic cancer in xenograft models, but 
after failure of the clinical trials, it was suggested that these previous data may have been biased (5). 
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Genetic models that recapitulate the heterogeneity and multistage nature of tumour progression are 
believed to be more predictive than xenograft models (14). Interestingly, genetic mouse models of 
neuroendocrine pancreatic cancer recently demonstrated that the ablation of MMP-9 gave rise to more 
invasive tumours (15). However, neuroendocrine tumours of the pancreas are a relatively rare condition, 
accounting for only 1-5% of the diagnosed pancreatic cancers, while the large majority of tumours are 
PDACs, arising from the exocrine cellular compartment (1). A well-characterized genetic mouse model 
of PDAC is the LSL-KrasG12D-LSL-Trp53R172H-Pdx1-Cre (KPC) mouse (16). Here, we crossed KPC 
mice with non-leaky MMP-9 knock-out mice in order to investigate the functional role of MMP-9 in the 
context of PDAC in avoidance of the complexities of pharmacological agents, such as inhibition of off-
targets, incomplete inhibition, and toxicity. We report that systemic ablation of MMP-9 has detrimental 
effects in PDAC because abrogation of MMP-9-mediated SCF-signalling in the bone marrow led to 
increased IL-6 levels in the host which activated STAT3 signalling in tumour cells and thereby promoted 
invasive growth and metastasis of PDAC. 
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Material and Methods 
Animal experiments. Mice were kept at the animal facility of Klinikum rechts der Isar (Munich, 
Germany) under specific and opportunistic pathogen-free conditions. Animal experiments were 
performed in compliance with the guidelines of the Tierschutzgesetz des Freistaates Bayern and 
approved by the Regierung von Oberbayern. During animal experiments investigators were unaware of 
the identity of animals and samples. The following transgenic mouse models were described in detail 
elsewhere: Pdx-1+/Cre;Kras+/LSL-G12D;Trp53+/LSL-R172H (‘KPC’) (16), and pure C57BL/6 non-
leaky MMP-9 knock-out mice (‘MMP-9-/-‘) mice (17). Female or male KPC mice were used at 5-6 
weeks (‘CP stage’), 8-10 weeks (‘PanIN stage’) or 12-14 weeks age (‘PDAC stage’) or 14-16 wks age 
(‘Advanced PDAC stage’); healthy littermates (Pdx-1+/Cre or Trp53+/LSL-R172H) served as controls. 
MMP-9-/- mice were used at 8-10 weeks age; wild-type littermates (MMP-9+/+) served as controls. To 
study the role of MMP-9 in PDAC, we cross-bred KPC mice with MMP-9-/- mice (17) to obtain 
C57BL/6-MMP9-/-/Pdx-1+/Cre;Kras+/LSL-G12D;Trp53+/loxP (‘KPCxMMP-9-/-‘) mice. To test the 
impact of pharmacological MMP-9 inhibition, female 8-10 weeks old DBA/2 mice were obtained from 
Charles River and treated daily for 14 days with inhibitor or vehicle control as described previously 
(8,18). In vivo invasive growth of PDAC cells in MMP-9-/- mice and MMP-9-kompetent littermates was 
tested by intravenous inoculation of 1x106 syngeneic KPC-derived 9801 or Panc02 pancreas carcinoma 
cells (19). Mice were sacrificed at the indicated time-points after tumour cell inoculation (in vivo 
invasion: 24 h; out-growth: 14 d), and tumour cells on the median liver lobe and the right lung lobe were 
X-Gal-stained and quantified as described previously (19).  
Cell lines, cell culture, in vitro assays. Bone marrow cells were harvested from femurs by flushing the 
bone cavity with PBS. Erythrocytes were lysed and BM cells were re-suspended in BBMM (Lonza) and 
seeded in uncoated tissue culture dishes. Where indicated, BM cell cultures were supplemented with 2.5 
ng/ml recombinant murine SCF (R&D Systems) and mRNA was extracted 2 h later. KPC-derived 
murine 9801 pancreas carcinoma cells (19) and the Panc02 cell line (20) were cultured as described 
previously. Cells were regularly tested for mycoplasma contamination (MycoTrace, PAA). Genetic 
MMP-9 ablation-induced invasive growth of pancreatic cancer 
 
 
 
6 
tagging, retroviral knock-down of MMP-9 (21) and lentiviral knock-down of IL-6R (19) in cells were 
achieved by lentiviral transduction as described previously. Where indicated, 20 ng/ml recombinant IL-
6 was added to the medium for 24 h prior to and during analysis. Motility and invasion were analysed 
through 3 µm Corning®TransWell inserts (Sigma Aldrich). For invasion assays, inserts were coated 
with coated with 1 mg/mL BD MatrigelTM Basement Membrane Matrix (BD Biosciences). 5x105 cells 
per well were added in FCS-free medium and allowed to migrate or invade towards the 10% FCS-
containing medium in the lower well for 24 h or 48 h, respectively. Cells were removed from the upper 
side of the membrane using a cotton stick. Cells migrated/invaded to the lower side were fixed with 
methanol, stained with DAPI, and counted under a microscope. Proliferation (in 10% FCS) and viability 
(in 0.1% FCS) over 96 h were determined by AlamarBlue Assays (ThermoFisher) according to the 
manufacturer´s instructions.  
Immunohistochemistry (IHC). IHC staining was previously described in detail (19). Briefly, sections 
were de-paraffinized, blocked and incubated with the following antibodies: SMA (Abcam), PCNA 
(Santa Cruz Biotechnology), CK19 (Developmental Studies Hybridoma Bank) or phosphor-STAT3 
(Cell Signalling Technology). Detection was done via polyclonal biotinylated secondary antibodies 
(anti-rabbit, Dako; anti-goat, Dako; anti-rat, Abcam), Streptavidin/HRP (Dianova) and DAB substrate 
(Dako). Counterstaining was done using Haematoxylin. 
RNA isolation, reverse transcription, and quantitative RT-PCR. Total RNA from cells was isolated 
using TRIzol (Life Technologies) according to the manufacturer’s instructions. Reverse transcription to 
cDNA was performed using High Capacity Reverse Transcription Kit (Applied Biosystems). qRT-PCR 
was performed using Universal TaqMan Mastermix (Roche), primers were designed using Probefinder 
v2.45 (http://qpcr.probefinder.com/roche3.html) and used in combination with the respective probes 
from Universal Probe Library (Roche). 
Protein Isolation, Immunoblotting, and ELISA. Total protein was isolated by sonification of cells in 
RIPA buffer followed by three freeze-thaw cycles. For collection of extracellular BM fluid, femurs were 
flushed with 1 ml PBS before cells and extracellular fluid were separated by centrifugation. Membrane 
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protein from the cells was isolated as previously described (22). The method used for Western Blotting 
was described previously (23). Briefly, 50 µg of total cell lysate, 40 µg of membrane fraction or 15 µg 
protein from BM extracellular fluid were electrophoretically separated, blotted onto nitrocellulose and 
probed with antibodies against α-Tubulin (Merck), SCF (Santa Cruz Biotechnology), phospho-p85, 
STAT3, phospho-STAT3, phospho-ERK1/2 (all from Cell Signalling Technology). Detection was done 
using Clarity ECL substrate (BioRad) in a ChemiDoc MP imaging system (BioRad). IL-6 levels were 
determined using the DuoSet ELISA Kit (R&D Systems) according to the manufacturer´s instructions. 
Zymography analysis. Tissues were weighted, placed into extraction tubes (Precellys Lysing Kit) and 
500 ml of buffer (150 mM NaCl, 50 mM Tris, 5 mM CaCl2, 0.05% Tween20, pH 7.5-HCl) was added 
to the samples. Tissues were homogenised with the Precellys 24 and supernatants were recovered (15 
min, 20000 g, 4°C). Prior to zymography analysis, the total protein content of the samples was 
determined with the method of Bradford and the samples were prepurified by gelatin affinity 
chromatography. For each sample, the equivalent of 120 µg protein was loaded onto a Micro Bio-Spin 
Chromatography Column (bio-rad) containing 40 µl of Gelatin-Sepharose® 4B beads (GE Healthcare) 
in equilibration buffer (50 mM Tris, 0.5 M NaCl, 10 mM CaCl2, 0.01% Tween 20, pH 7.5-HCl). As an 
internal reference, 800 pg of proMMP-9 ΔOGHem was added and this mixture was incubated for 20 
min at room temperature. Next, the samples were washed 3 times with 500 µl washing buffer 1 (50 mM 
Tris, 0.5 M NaCl, 10 mM CaCl2, 0.05% Tween 20, pH 7.5-HCl) and once with washing buffer 2 (50 
mM Tris, 10 mM CaCl2, 0.05% Tween 20, pH 7.5-HCl). Finally, the samples were eluted in 20 µl non-
reducing loading buffer (0.125M Tris-HCl pH 6.8, 4% SDS, 0.01% bromophenol blue, 20% glycerol) 
(24). The prepurified samples were loaded onto 7.5% polyacrylamide gels which contain 0.1% gelatin. 
After electrophoresis the gels were washed twice for 20 minutes with 2.5% Triton X-100 to remove 
SDS, and incubated overnight at 37°C in incubation buffer (50mM Tris-HCl, pH 7.5, 10mM CaCl2, 
0.02% NaN3, 1% Triton X-100) for gelatin degradation. Finally, the gels were stained with the PhastGel 
Blue R-350 staining kit (GE Healthcare) and the densities of the bands were analysed with the 
ImageQuant TL software (GE Healthcare) (25). The concentrations of MMP-9 and MMP-2 were 
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calculated based on the density of the bands, the recovery of the internal reference after co-
prepurification and a dilution series of recombinant wild-type MMP-9 of known concentration. MMP-
9ΔOGHem and wild-type MMP-9 have been described in detail in previous publications (26). Gelatin 
gel zymography was performed twice for each sample. 
Statistical analysis: The number of biological replicates (number of animals per group or number of 
independent repetitions of in vitro experiments, respectively) is listed in the figure legends. Each 
biological replicate consisted of at least three technical replicates. Data sets were tested for normality of 
distribution and compared by one-way analysis of variance (One-way ANOVA), in case of multiple 
groups followed by Bonferroni post hoc analysis. Values of p < 0.05 were considered significant. 
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Results 
 
MMP-9 is expressed in murine PDAC  
First, we tested whether MMP-9 is expressed in the KPC mouse model of PDAC. Pancreatic 
proMMP-9 protein levels in C57BL/6J-LSL-KrasG12D-LSL-Trp53R172H-Pdx1-Cre (KPC) mice were 
already elevated at the stage of pre-cancerous pancreatitis and PanIN lesions, and further increased 
during progression to full-blown PDAC (Fig.1A). Concomitantly, we observed induction of proMMP-
2 (Supplementary Fig.S1). Within pancreatic lesions of KPC mice, MMP-9 transcripts were present in 
tumour cells as well as in cells of the desmoplastic stroma (Fig.1B). Thus, MMP-9 was present in murine 
PDAC and its expression correlated with disease progression.  
 
Loss of MMP-9 promotes invasive growth of PDAC in vivo  
To explore the role of MMP-9 in the progression of PDAC, we cross-bred KPC mice with a 
non-leaky MMP-9 knock-out line (Dubois et al 1999) to obtain C57BL/6-LSL-KrasG12D-LSL-
Trp53R172H-Pdx1-Cre-MMP-9-/- (KPCxMMP-9-/-) mice. First, we compared tumour progression with 
and without MMP-9 at the age of 8 weeks. Macroscopically, pancreata from KPCxMMP-9-/- mice were 
dramatically enlarged containing palpable tumour masses while KPC pancreata appeared 
macroscopically normal (Fig.2A). Gross histological analysis by HE staining showed that pancreata of 
8 weeks old KPC mice contained PanIN lesions surrounded by normal pancreatic tissue whereas 
KPCxMMP-9-/- mice exhibited large areas of dedifferentiated, invasive PDAC and a strong desmoplastic 
reaction (Fig.2B). Invasiveness of the tumours was determined histologically by scoring the circularity 
of the tumour borders as previously shown for neuroendocrine pancreatic tumours (15). Tumours from 
8 weeks old KPCxMMP-9-/- mice were profoundly more invasive than the PanIN lesions in MMP-9-
competent KPC mice as reflected by a decreased circularity (Fig. 2C). To determine whether this 
increased invasiveness of KPCxMMP-9-/- tumours is a result of the observed promoted disease 
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progression or attributable to MMP-9-deficiency, we compared MMP-9-deficient carcinomas of 8 
weeks old KPCxMMP-9-/- mice with advanced MMP-9-competent carcinomas from 14-16 weeks old 
KPC mice. Interestingly, the MMP-9-deficient pancreatic carcinomas were still profoundly more 
invasive (Fig. 2C). In accordance with the gross histological analysis, immunohistochemical analysis 
of specific progression markers showed that enhanced tumour growth in KPCxMMP-9-/- mice was 
accompanied by increased numbers of CK19+ tumour cells and an increased PCNA index (Fig.2D). The 
increased areas of desmoplastic stroma in MMP-9-deficient tumours were reflected by an increased 
content of SMA+ myofibroblasts (Fig.2E). Taken together, ablation of MMP-9 promoted progression 
and invasive growth of pancreatic tumours. 
 
Ablation of MMP-9 does not directly promote invasive growth of PDAC cells in vitro  
Invasive growth is defined as a complex biological program which instructs cells to migrate, 
invade, proliferate and survive (27). First, we tested whether ablation of MMP-9 could directly unleash 
invasive growth of PDAC cells in vitro. MMP-9 was knocked down by lentiviral shRNAi in the murine 
KPC-derived pancreatic tumour cell line 9801 (19) (Fig. 3A). Knock-down of MMP-9 did not induce 
invasive growth but instead led to reduced proliferation (Fig.3B), viability (Fig.3C), migration (Fig.3D) 
and invasion (Fig.3E) of 9801 PDAC cells in vitro. Likewise, knock-down of MMP-9 in a second cell 
line, Panc02 murine pancreatic carcinoma cells (20), reduced invasive growth of the cells 
(Supplementary Fig. S2).  
 
MMP-9-deficient hosts exhibit increased levels of IL-6 in bone marrow and plasma 
Ablation of MMP-9 in tumour cells did not directly promote invasive growth. We thus 
hypothesized that systemic alterations in the MMP-9-deficient hosts promoted the invasive growth of 
PDAC. Previously, we have shown that MMP-9 knock-out can result in specific induction of IL-6 in the 
bone marrow (BM) (28). Noteworthy, elevated systemic and tumoural IL-6 levels derived from the BM 
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were recently shown to be central to PDAC initiation and progression (29) by acting on various tumour-
promoting processes including tumour cell proliferation, survival, migration, invasion (i.e. invasive 
growth) as well as angiogenesis, activation of stromal fibroblasts, and immune invasion (30). Indeed, 
IL-6 levels in plasma and BM of tumour-free MMP-9-/- animals were increased (Fig.4A). Noteworthy, 
plasma IL-6 levels in MMP-9-deficient tumour-bearing KPC mice were increased between 11- to 20-
fold as compared to MMP-9-competent KPC mice (Fig.4B). We next tested whether the IL-6 plasma 
level in MMP-9-/- mice (~20 pg/ml) was sufficient to directly promote invasive growth of PDAC cells. 
KPC-derived 9801 cells in vitro showed increased migration, invasion, and proliferation in the presence 
of 20 ng/ml IL-6 (Fig.4C). Knock-down of IL-6R in 9801 cells (Fig.4D) abolished the IL-6-induced 
invasive growth in vitro (Fig.4E, F). IL-6-induced invasive growth is mediated via activation of the 
STAT3 pathway (30). STAT3 was not active in the PDAC cells in vitro but could be induced by 
stimulation with IL-6 (Fig. 5A) followed by transcription of the STAT3 target genes cMet, Vegfa, Car9, 
Hif1a, Vimentin, and Icam-1 (Fig. 5B) in an IL-6R-dependent manner. KPCxMMP-9-/- tumours 
exhibited strong STAT3 activation in tumour cells and infiltrating immune cells as compared to MMP-
9-competent KPC mice (Fig. 5C). Taken together, these results indicate that increased IL-6 levels in 
MMP-9-deficient hosts are able to promote invasive growth via IL-6R-dependent STAT3 activation in 
PDAC cells. 
 
Loss of MMP-9-dependent SCF-signalling via STAT3 in the bone marrow is compensated by 
induction of IL-6 
Next, we sought to determine why loss of MMP-9 resulted in induction of IL-6 in the BM. BM 
homeostasis is largely dependent on MMP-9 as the sheddase of stem cell factor (SCF) (31) which is 
necessary for proliferation and differentiation of hematopoietic stem cells via binding to stem cell factor 
receptor (SCF-R). Indeed, loss of MMP-9 led to a significant reduction of soluble SCF within BM 
extracellular fluid while the membrane-bound fraction of SCF was increased (Fig. 6A). Potential 
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consequences of this MMP-9-deficiency-induced ablation of SCF shedding include abrogation of 
downstream signalling cascades maintaining proliferation and survival of BM cells, such as STAT3, 
PI3K and ERK (32). We found that phosphorylation status of the PI3K regulator p85 and ERK was 
reduced in BM MMP-9-/- mice, whereas STAT3 activation was enhanced (Fig. 6B). STAT3 expression 
remained unaltered (Fig. 6C). Thus, MMP-9-/- mice maintained STAT3 activation. In addition, MMP-
9-/- mice show no defects of the hematopoietic system in the steady-state (31). This led us to hypothesize 
that reduction of soluble SCF in MMP-9-deficient bone marrow is compensated by induction of another 
molecule, which can signal via STAT3, namely IL-6. We thus tested whether SCF deprivation could in 
principle induce IL-6 in BM cells. Indeed, BM cells cultured in absence of SCF expressed significantly 
higher levels of IL-6 while addition of SCF reduced IL-6 expression (Fig. 6D). To further investigate 
whether induction of IL-6 in the BM upon ablation of MMP-9 was a result of genetic manipulation, we 
treated mice with synthetic MMP inhibitors of varying selectivity for MMP-9. Inhibitors with a higher 
selectivity for MMP-9 led to a slight (Ro206-0222) or significant (SB-3CT) increase of IL-6 expression 
(Fig. 6E), while treatment with the less MMP-9- specific inhibitors (BB94 or Ro28-2653) had negligible 
effects. We conclude that induction of IL-6 in the BM occurs upon ablation of MMP-9.  
 
Promotion of invasive growth in MMP-9-deficient hosts is dependent on IL-6R 
In the final set of experiments, we determined whether increased IL-6 levels in MMP-9-deficient 
hosts were directly able to promote invasive growth of tumour cells. We employed the 9801 and Panc02 
PDAC cells in experimental metastasis assays in MMP-9 knock-out mice. Tumour cells were lacZ-
tagged to enable highly sensitive detection at the single cell level (33). In MMP-9-deficient mice, we 
observed an induction of in vivo invasion of 9801 cells (Fig.7A) and Pan02 cells (Fig.7B) into livers 
and lungs. In addition, we observed promoted outgrowth of 9801 (Fig.7C) and Panc02 metastases 
(Fig.7D) in MMP-9-/- mice. Interestingly, invasion of MMP-9-deficient tumour cells was also promoted 
in MMP-9-deficient hosts (Fig.7E). We next determined the role of IL-6/IL-6R signalling in the 
induction of invasive growth in MMP-9-deficient hosts. Knock-down of IL-6R in 9801 cells abolished 
MMP-9 ablation-induced invasive growth of pancreatic cancer 
 
 
 
13 
the invasive growth-promoting effects of MMP-9-deficient hosts in vivo (Fig.7F). Taken together, 
ablation of MMP-9 in the host, but not in the tumour cell itself, promoted invasive growth of pancreatic 
tumour cells via induction of IL-6. 
 
Discussion 
 
In the present study we addressed the consequences of specific long-term loss-of-function of MMP-9 in 
the context of PDAC. PDAC is among the most aggressive malignancies and currently no effective 
treatment options exist for this fatal disease (1) so that new therapeutic targets are urgently needed (2,3). 
Inhibition of MMP-9 is currently tested as therapeutic approach in clinical trials (11), despite the seminal 
failure of MMP inhibitors in the past (5), because increased selectivity of inhibitors for target MMPs is 
thought to be key to the expected anti-tumourigenic and anti-metastatic therapeutic potential of MMP 
inhibition (8,9). However, functions of specific MMPs can be context-dependent (28). Thus, critical 
assessment of potential target MMPs in relevant disease contexts is imperative to their evaluation as 
therapeutic targets (12). Here, we report that even highly specific, complete ablation of MMP-9 has 
detrimental effects in PDAC and dramatically promoted disease progression in a clinically relevant 
genetic PDAC mouse model. We identified the underlying mechanism and report that ablation of MMP-
9 in tumour cells did not directly promote invasive growth. Instead, systemic ablation of MMP-9 induced 
a tumour-promoting host microenvironment by inducing detrimental locoregional alterations in the BM, 
where loss of MMP-9 activity led to impaired SCF shedding. The resulting distortion of SCF-release 
induced IL-6 expression in the BM leading to increased systemic IL-6 to a level that was able to activate 
STAT3 signalling and induce invasive growth of pancreatic tumour cells. Thus, ablation of systemic 
MMP-9 initiated a fatal communication between the physiological function of MMP-9 in BM 
homeostasis and invasive growth of tumour cells via the IL-6/IL6R/STAT3 axis. 
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We used a non-leaky knock-out mouse line that was 13 times back-crossed into C57BL/6J 
background and corresponding WT mice to determine the consequences of specific, long-term inhibition 
of MMP-9 on PDAC progression in order to model a `perfect therapy’, mimicking full and selective 
MMP-9 inhibition while avoiding the complexities of pharmacological agents, such as unselective off-
target binding, incomplete inhibition and toxicity. Subsequent dissection of the roles of tumour cell 
MMP-9 vs. host MMP-9 revealed that these play controversial roles in pancreatic cancer progression: 
ablation of MMP-9 in PDAC cells reduced their invasive growth, which would be in accordance with 
the common notion of a pro-invasive and growth-promoting role of MMP-9 in cancer (9–11). However, 
systemic ablation of MMP-9 created a tumour-promoting microenvironment that facilitated invasive 
growth and metastasis of PDAC cells. In KPCxMMP-9-/- mice both host and tumour cells are MMP-9-
deficient, and invasive growth was dramatically promoted. This suggests that pro-tumourigenic 
alterations in the MMP-9-deficient host dominate over the tumour-inhibiting effects of MMP-9-
deficiency in tumour cells ultimately resulting in promotion of disease upon systemic loss of MMP-9 
function. Additional studies have already hinted that systemic loss of MMP-9 activity can increase the 
aggressiveness of malignant disease. In a genetic mouse model of neuroendocrine pancreatic tumours, 
knock-out of MMP-9 impaired tumour angiogenesis but promoted tumour invasion in association with 
a shift in inflammatory cell content to cathepsin-expressing CD11b/Gr1-positive cells (15). 
Neuroendocrine tumours are relatively rare (1-5% of pancreatic cancers) while the KPC model used in 
the current study is a widely used ´gold standard´ model for PDAC (14,34), the most common form of 
pancreatic cancer accounting for >90% of the diagnosed cases. Due to differences in the cellular origin, 
the biology of exocrine and endocrine pancreatic tumours is likely to be different so that it seems that 
ablation of MMP-9 promotes aggressiveness of various pancreatic tumour types. In addition, several 
studies have suggested that ablation of MMP-9 has detrimental effects in various other tumour entities: 
In a model of skin carcinogenesis, MMP-9 deficiency decreased the total number of tumours but the 
emerging tumours were significantly more aggressive (35) and in a genetic model of prostate cancer, 
MMP-9-deficiency increased the number of invasive foci (36). Moreover, MMP-9 clearly plays a 
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protective role in colitis-associated cancer (37). Taken together, the suitability of MMP-9 per se as a 
therapeutic target in cancer and especially in pancreatic cancer, is highly questionable. Thus, we suggest 
that MMP-9 inhibition can only be a valid strategy against pancreatic cancer when combined with 
effective and highly specific targeting of tumour cells. 
 
MMP-9-deficient mice exhibited increased IL-6 levels in the BM. Addressing the underlying 
mechanism we found that loss of MMP-9-dependent SCF-signalling in the BM of MMP-9-deficient 
mice led to reduced activation of PI3K/Akt and ERK pathways, but increased STAT3-activation. In 
addition, despite distortion of this central MMP-9-dependent pathway in BM homeostasis, MMP-9-
deficient mice do not show any defects in the immune system under steady-state conditions (31). We 
thus propose that abrogation of MMP-9-mediated SCF-release is compensated by induction of IL-6 to 
maintain STAT3 signalling and thereby BM homeostasis and function. In accordance, absence of SCF 
was sufficient to induce IL-6 expression BM cells. IL-6 levels as seen in MMP-9-deficient mice were 
sufficient to induce invasive growth and STAT3 activation in pancreatic cancer cell lines in vitro. IL-6 
was in fact discovered as a hybridoma and plasmacytoma growth factor (38). IL-6 owns a broad 
spectrum of pathobiological activities and can affect various tumour-promoting processes including 
tumour cell proliferation, survival, migration, invasion (i.e. invasive growth) as well as angiogenesis, 
activation of stromal fibroblasts, and immune invasion (30). Invasive growth is defined as a complex 
biological program concomitantly instructing cells to migrate, invade, proliferate and survive (27). IL-
6 was shown to induce invasive growth of tumour cells in skin cancer (39) and breast carcinomas (40) 
and was identified as a central driver of PDAC initiation and progression (29,30). IL-6 mediates its 
potent effects in PDAC progression via STAT3 activation and both, ablation of IL-6 and of STAT3 are 
essential drivers of pancreatic tumour formation in KrasG12D-driven pancreatic carcinogenesis (29). We 
observed no basal STAT3 activation in pancreatic cancer cells in vitro. In accordance, it was suggested 
previously that STAT3 activation in pancreatic cancer cells is non-cell-autonomous but depends on IL-
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6 derived from the microenvironment (29). Importantly, not only genetic but also pharmacologic 
inhibition of MMP-9 induced IL-6 expression in the bone marrow. In conclusion, ablation of systemic 
MMP-9 dramatically promoted invasive growth and metastasis of PDAC tumours via distant 
locoregional alterations in the BM. We thus believe that such detrimental net effects in the protease web 
upon MMP-9 ablation are an important caveat for the use of MMP-9 as therapeutic target in pancreatic 
cancer. 
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Figure Legends. 
 
Figure 1: MMP-9 was present in tumours of KPC mice 
(A) MMP-2 and MMP-9 protein levels in pancreas lysates from KPC (+) mice or healthy (-) littermates 
at an age of 5-6 weeks, 8-10 weeks and 12-14 weeks (n = 3 per group). Quantitative gelatine 
zymography. Columns, mean; Bars, SEM. Statistical testing by One-way ANOVA: *, p<0.05; **, 
p<0.01. 
(B) Visualisation of MMP-9 mRNA in tissue sections from KPC mice by in situ hybridization. 
 
Figure 2: Invasive growth of MMP-9-deficient pancreatic tumours in mice 
(A) Whole mounts of pancreata from 8 weeks old KPC and KPCxMMP-9-/- mice (n = 6). Representative 
images. 
(B) HE stained sections from pancreata from 8 weeks old KPC and KPCxMMP-9-/- mice (n = 6). 
Representative images. S, desmoplastic stroma; N, normal pancreatic tissue; *, PanIN lesion; #. Invasive 
PDAC. Bars, 100 µm. 
(C) Tumour circularity of lesions from 8 weeks old KPCxMMP-9-/- mice (n = 6) compared to 8 weeks 
old (n = 5) and 14-16 weeks old (n = 5) KPC mice.  
(D) CK19+ tumour cells and PCNA+ proliferating cells in sections from pancreata from 8 weeks old 
KPC and KPCxMMP-9-/- mice (n = 5). Top, quantification; bottom, representative images. Bars, 50 µm. 
(E) SMA+ stromal cells in sections from pancreata from 8 weeks old KPC and KPCxMMP-9-/- mice 
(n = 5). Left, quantification; right, representative images. Bars, 50 µm. 
(C-E) Columns, mean; Bars, SEM. Statistical testing by One-way ANOVA: *, p<0.05; **, p<0.01. 
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Figure 3: Knock-down of MMP-9 did not promote invasive growth of  
pancreatic cancer cells in vitro 
(A-E) Analysis of invasive growth of 9801 pancreatic carcinoma cells after lentiviral knock-down of 
MMP-9 (n = 3).  
(A) Lentiviral knock-down of MMP-9 in 9801 cells. MMP-9 mRNA determined by qRT-PCR.  
(B) Proliferation determined by AlamarBlue assays. 
(C) Viability determined by AlamarBlue assays. 
(D) TransWell Migration. 
(E) TransWell Invasion. 
(A,C-E) Columns, mean; Bars, SEM.  
(A-E) Statistical testing by One-way ANOVA: *, p<0.05; **, p<0.01. 
 
Figure 4: IL-6 levels in MMP-9-deficient hosts promoted invasion and growth of PDAC cells  
(A) IL6 levels of MMP-9-/- mice and MMP-9-kompetent littermates determined in plasma by ELISA 
(left) and in bone marrow by qRT-PCR (right) (n = 5).  
(B) IL-6 plasma levels in KPC and KPCxMMP-9-/- mice determined by ELISA (n = 3 per group). 
(C) Invasive growth of 9801 pancreatic carcinoma cells in presence of 20 ng/ml IL-6 (n = 3).  
Proliferation determined by AlamarBlue assays (left), TransWell Migration (middle), TransWell 
Invasion (right). 
(D) Lentiviral knock-down of IL-6R in 9801 cells. IL6R mRNA determined by qRT-PCR (n = 3). 
(E,F) Invasive growth of 9801 pancreatic carcinoma cells in presence of 20 ng/ml IL-6 (n = 3).  
(E) Proliferation determined by AlamarBlue assays,  
(F) TransWell Migration (left), TransWell Invasion (right) 
(A-D, F) Columns, mean; Bars, SEM.  
(A-F) Statistical testing by One-way ANOVA: *, p<0.05; **, p<0.01. 
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Figure 5: Activation of STAT3 in pancreatic cancer cells via IL-6/IL-6R 
 (A) P-STAT3 levels in 9801 pancreatic carcinoma cells in presence or absence of 20 ng/ml IL-6 
determined by immunoblotting (n = 3). Blots were cropped to the indicated bands. 
(B) Expression of STAT3 downstream targets cMet, Vegfa, Car9, Hif1a, Vimentin, and Icam-1 in 9801 
pancreatic carcinoma cells in presence or absence of 20 ng/ml IL-6 determined by qRT-PCR (n = 3). 
Columns, mean; Bars, SEM. Statistical testing by One-way ANOVA: *, p<0.05; **, p<0.01. 
(C) P-STAT3 staining by IHC on sections from pancreata from 8 weeks old KPC and KPCxMMP-9-/- 
mice (n = 3). Bars, 100 µm. 
 
Figure 6: Induction of IL-6 and STAT3 in the bone marrow upon ablation of MMP-9 
(A) Extracellular and membrane-bound SCF in bone marrow fractions from MMP-9-/- mice and MMP-
9-kompetent littermates determined by immunoblotting (n = 5). Left, representative (of three) blots; 
right, densitometrical analysis. Blots were cropped to the indicated bands. 
(B) P-STAT3, P-p85 and P-ERK levels in bone marrow lysates from MMP-9-/- mice and MMP-9-
kompetent littermates determined by immunoblotting. Representative (of three) blots. Blots were 
cropped to the indicated bands. 
(C) STAT3 and P-STAT3 levels in bone marrow lysates from MMP-9-/- mice and MMP-9-kompetent 
littermates determined by immunoblotting (n = 5). Left, representative (of three) blots; right, 
densitometrical analysis. Blots were cropped to the indicated bands. 
(D) IL-6 mRNA in bone marrow cells in the presence or absence of 2.5ng/ml SCF determined by qRT-
PCR (n = 3). 
(E) IL-6 levels in bone marrow lysates from MMP-9-kompetent mice after treatment with MMP 
inhibitors and un-treated MMP-9-/- mice (n = 5) determined by ELISA.  
(A,C-E) Columns, mean; Bars, SEM. Statistical testing by One-way ANOVA: *, p<0.05; **, p<0.01. 
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Figure 7: Increased metastasis formation of pancreatic cancer cells in MMP-9-deficient hosts 
depended on IL-6R 
(A-F) Invasive growth of pancreatic carcinoma cells in MMP-9-/- mice and MMP-9-kompetent 
littermates. Experimental metastasis assays (n = 6). Columns, mean; Bars, SEM. Statistical testing by 
One-way ANOVA: *, p<0.05; **, p<0.01. 
(A) In vivo invasion of 9801 cells into livers (left) and lungs (right). 
(B) In vivo invasion of Panc02 cells into livers (left) and lungs (right). 
(C) Out-growth of metastatic colonies of 9801 cells in livers (left) and lungs (right). 
(D) Out-growth of metastatic colonies of Panc02 cells in livers (left) and lungs (right). 
(E) In vivo invasion of 9801 cells with and without knock-down of MMP-9 into livers. 
(F) In vivo invasion of 9801 cells with and without knock-down of IL6R into livers. 
 
Visual Overview: Loss of host MMP-9 promotes invasive growth and metastasis  
in pancreatic cancer by inducing IL-6 in the bone marrow.  
Proposed mechanism: loss of host MMP-9 abrogates SCF shedding in the bone marrow which leads to 
induction of IL-6. Elevated IL-6 levels activate STAT3 in tumour cells in the pancreas and in the 
circulation thereby promoting pancreatic tumour progression as well as metastasis. 
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Supplementary Figure Legends. 
 
Supplementary Figure S1: MMP2 in KPC mice 
MMP-2 quantification from gelatine zymography analysis shown in Figure 1A. 
 
Supplementary Figure S2: Knock-down of MMP-9 did not promote invasive growth of  
Panc02 pancreatic cancer cells in vitro 
(A-E) Analysis of invasive growth of Panc02 pancreatic carcinoma cells after lentiviral knock-down 
of MMP-9. 
(A) Lentiviral knock-down of MMP-9 in Panc02 cells. MMP-9 mRNA determined by qRT-PCR.  
(B) Proliferation determined by AlamarBlue assays. 
(C) Viability determined by AlamarBlue assays. 
(D) TransWell Migration. 
(E) TransWell Invasion. 
(A,C-E) Columns, mean; Bars, SEM.  
(A-E) Statistical testing by One-way ANOVA: *, p<0.05; **, p<0.01. 
 
